The characterisation of IL6-dependent signalling has suggested that specific targeting of its trans-signalling route might be a good strategy to block this cytokine’s pro-cancer effects without altering other important roles in homeostasis that normally rely on classic signalling [296]. The gene discussed is IL6; the disease is cancer.